期刊
PHYSIOLOGICAL GENOMICS
卷 50, 期 1, 页码 20-34出版社
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/physiolgenomics.00039.2017
关键词
chronic kidney disease; microRNA; renal fibrosis
资金
- National Institutes of Health [HL-36279, DK-104184, AG-050049, P20GM-104357]
- American Heart Association [16GRNT31200036]
- National Natural Science Foundation of China [81270939, 81472983, 81571625]
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104357] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [R21AG050049] Funding Source: NIH RePORTER
Chronic kidney disease (CKD), defined as reduced glomerular filtration rate, is increasingly becoming a major public health issue. At the histological level, renal fibrosis is the final common pathway leading to end-stage renal disease, irrespective of the initial injury. According to this view, antifibrotic agents should slow or halt the progression of CKD. However, due to multiple overlapping pathways stimulating fibrosis, it has been difficult to develop antifibrotic drugs that delay or reverse the progression of CKD. MicroRNAs (miRNAs) are small noncoding RNA molecules, 18-22 nucleotides in length, that control many developmental and cellular processes as posttranscriptional regulators of gene expression. Emerging evidence suggests that miRNAs targeted against genes involved in renal fibrosis might be potential candidates for the development of antifibrotic therapies for CKD. This review will discuss some of the miRNAs, such as Let-7, miR-21,-29, -192, -200,-324, -132, -212, -30, -126, -433, -214, and -199a, that are implicated in renal fibrosis and the potential to exploit these molecular targets for the treatment of CKD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据